Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Financing Activities (2019 - 2025)

Black Diamond Therapeutics' Cash from Financing Activities history spans 5 years, with the latest figure at -$196000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 167.35% year-over-year to -$196000.0; the TTM value through Dec 2025 reached -$146000.0, down 100.57%, while the annual FY2025 figure was -$146000.0, 100.57% down from the prior year.
  • Cash from Financing Activities reached -$196000.0 in Q4 2025 per BDTX's latest filing, down from $134000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $21.4 million in Q2 2024 to a low of -$252000.0 in Q3 2024.
  • Average Cash from Financing Activities over 3 years is $2.9 million, with a median of $134000.0 recorded in 2025.
  • The largest YoY upside for Cash from Financing Activities was 153.17% in 2025 against a maximum downside of 167.35% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $481000.0 in 2021, then tumbled by 39.5% to $291000.0 in 2024, then tumbled by 167.35% to -$196000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Cash from Financing Activities are -$196000.0 (Q4 2025), $134000.0 (Q3 2025), and -$116000.0 (Q2 2025).